MicrobiotiX strives to develop treatments for global intractable diseases such as multidrug-resistant bacterial infections, autoimmune diseases and cancer
Phage, Microbiome & Beyond
Bacteriophage, also known simply as a phage, is a term referring to a virus whose host cell is a bacterium. Bacteriophages have the same wide domain as the bacteria they infect, inhabiting various natural ecosystems. Bacteriophage is a material derived from nature and is harmless to the human body because it already exists within the human body. Bacteriophage can selectively infect specific bacterial strains. This imparts the ability to eliminate antibiotic-resistant bacteria, while reducing the antibiotic dose taken by the patient.
The Sea of Phages THE PHAGEOME
Healthy people maintain a stable and balanced intestinal microbial ecosystem (microbiome). In other words, changes in the intestinal core bacteriophage and microbiome are delicately intertwined with human health (metabolites and immune system) Bacteriophages are used to balance and change intestinal microbiome through targeted bacterial removal, symbiosis with bacteria, and modulation.
Healthy Gut Phageome
Citation : Healthy human gut phageome Pilar Manrique, Benjamin Bolduc, Seth T. Walk, John van der Oost, Willem M. de Vos, Mark J. Young Proceedings of the National Academy of Sciences Sep 2016, 113 (37) 10400-10405; DOI: 10.1073/pnas.1601060113span>
Healthy people share of key phages
Patients with Ulcerative colitis share of key phages
Patients with Crohn’s disease share of key phages
Our pipeline will be expanded rapidly through the analysis of 1,000 new pathogens per month and discovering effective phages to fight against them. (NGS/PCS analysis to phage vs. microbiome, taxonomy, healthy patient phage comparison) to discover candidate drug substances and build optimized CMC to produce through our GMP.
Development of a Cure for Untreatable Diseases
MicrobiotiX aims to develop various treatments for untreatable diseases through bacteriophages that can target gram-negative, multidrug-resistant bacteria and through microbiome modulation to treat: pneumonia, sepsis, IBD, autism, obesity, diabetes, colon cancer, etc.
MP001 - Pneumonia Including cystic fibrosis
Composition Fixed rate cocktail of 3 types of phages Clinical use indications acute pneumonia infected with multidrug-resistant P. aeruginosa Genetic modification natural, unmodified lytic bacteriophages Target patient All age groups who are infected with multidrug-resistant Pseudomonas Aeruginosa
Dosage form liquid, 10 ml vial Combined administration Antibiotics Storage duration and method 2 years, 2-8 Celsius